Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting ...

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes ...

It is time for the agency to start thinking like an innovator, not an impediment to innovation. By modernizing and ...

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and ...

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA ...

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

Number 5: Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for ...

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to ...

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...